Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview

Figure 1 Galectin-3 and neuro-immuno-metabolic crosstalk. A and B: Considering the aspects of neuroprogression in schizophrenia, antipsychotics (APs) could have a beneficial role in improving cognitive functioning (A), but also, with galectin (Gal-3), could participate in undesired effects of immunometabolic disturbances (B); C: A potential cascade of metabolic syndrome (Sy) onset could be through the processes of glycosylation, Gal-3 elevation in the circulation, and secretion of proinflammatory cytokines, which individually and together could lead to cognitive deterioration.